[ad_1]
ORLANDO, Fla. / ACCESSWIRE / March 24, 2023 / RedChip Companies airs a new interview with BioVie Inc. Bibi iRemedy will air on Bloomberg TV’s The RedChip Money Report® on Saturday, March 25 at 7:00 PM ET. Bloomberg TV is available in an estimated 73 million households nationwide.
The full interview can be accessed at:
About RedChip Money Report®
The RedChip Money Report® is produced by RedChip Companies Inc., an international investor relations and media company with 30 years of experience focused on: Discover tomorrow’s best chips today™. The RedChip Money Report® provides insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, and featured interviews with public company executives.
About BioV Co., Ltd.
BioV Co., Ltd. Bibi is a clinical-stage company developing innovative drug therapies for the treatment of neurological, neurodegenerative and advanced liver disease. In neurodegenerative diseases, the company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (including TNF signaling), which leads to neuroinflammation and insulin resistance, but inhibits their homeostatic functions (insulin signaling, neuron growth and survival, etc.). Both are responsible for Alzheimer’s and Parkinson’s disease. We conducted a randomized, double-blind, placebo-controlled, parallel-group, multicenter potential study to evaluate his NE3107 in patients with mild to moderate Alzheimer’s disease (NCT04669028) A pivotal Phase 3 study is underway. At the Clinical Trials in Alzheimer’s Disease (CTAD) Annual Conference in December 2022, a phase 2 investigator-initiated trial showing that patients treated with NE3107 experienced improvements in cognitive function and biomarker levels ( NCT05227820) results have been announced. An estimated 6 million Americans suffer from Alzheimer’s disease. A phase 2 trial of NE3107 in Parkinson’s disease (NCT05083260) was completed and presented in December 2022. Topline data show that exercise in patients treated with a combination of NE3107 and levodopa versus those treated with levodopa alone showed clinically meaningful improvement in control. Drug-related adverse events. In liver disease, the Company’s orphan drug candidate BIV201 (continuous infusion terlipressin), which has FDA Fast Track status, is being evaluated in a US Phase 2b trial for the treatment of refractory ascites due to cirrhosis. BIV201 is administered as a patent-pending liquid formulation. This active ingredient is approved in the United States and approximately 40 countries for complications associated with advanced cirrhosis. For more information, please visit http://www.bioviepharma.com/.
About i Remedy
iRemedy is actively committed to disrupting and positively transforming the medical supply chain industry through the creation and support of an open, fair and fully transparent hypermarketplace for the sale and purchase of medical and healthcare products. is a leading, technology-driven healthcare and medical products distributor. Supply to Government Agencies, Care Providers, and Consumers.
By leveraging breakthrough innovations that combine the ease and convenience of e-commerce, iRemedy provides customers with access to over one million (and growing) high-quality products. Trusted and relied upon.
Products include disposable medical supplies, medical devices, durable medical devices, surgical devices, health monitoring devices, wound care products, dental devices and supplies, retail health care products, medical and surgical apparel, and office supplies. It is included.
For more information about the company, please visit https://iremedy.com/.
About Red Chip
RedChip Companies, an Inc. 5000 company, is an international investor relations, media and research firm focused on micro-cap and small-cap companies. For 30 years, RedChip has provided clients with tangible, measurable results. Our newsletter, the RedChip Money Report, is delivered online to 60,000 investors weekly. RedChip has developed the industry’s most comprehensive service platform for micro-cap and small-cap companies. These services include: A global distribution network for stock research. Retail and institutional roadshows in major US cities. Outbound marketing to stockbrokers, RIAs, institutions, and family offices. A digital media investor relations platform that has generated millions of unique investor opinions. Investor webinars and group calls. The RedChip Money Report, a weekly TV show on Bloomberg USA. Television commercials in local and national markets. Corporate and product videos. website design; traditional investor relations services include writing press releases, writing investor presentations, scripting quarterly conference calls, strategic consulting, fundraising, etc.
For more information on RedChip products and services, please visit:
https://www.redchip.com/corporate/investor_relations
“Discover tomorrow’s best chips today”™
contact:
Dave Gentry
red chip companies
1-800-RED-CHIP (733-2447)
or 407-491-4498
info@redchip.com
sauce: red chip
View source version on accesswire.com:
https://www.accesswire.com/745609/BioVie-Inc-and-iRemedy-Interviews-to-Air-on-Bloomberg-US-on-the-RedChip-Money-ReportR
[ad_2]
Source link
